Ask AI
ProCE Banner Activity

Ready, Set, Complement! Novel C5 Inhibitors in Generalized Myasthenia Gravis

Slideset

Generalized myasthenia gravis presents ongoing treatment challenges, particularly for patients with persistent symptoms despite standard therapies. In these downloadable slides, explore the role of complement inhibition, review clinical evidence for approved and investigational C5 inhibitors, and examine practical considerations for individualized treatment selection, safety, adherence, and long-term patient-centered care.

Released: October 30, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for U.S.-based neurologists, neuromuscular specialists, advanced practice providers, nurses, and pharmacists caring for patients with MG.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the unmet medical needs in the care of people with MG, including those who do not adequately respond to first-line therapies

  • Differentiate novel C5 inhibitors based on their clinical characteristics, such as efficacy, safety profiles, and schedules/routes of administration

  • Formulate individualized care plans for people with gMG that integrate evidence-based use of C5 inhibitors, considering mechanism of action, efficacy, safety, and evolving clinical roles to support long-term adherence and improved quality of life